Citigroup Maintains Neutral on Bristol-Myers Squibb, Raises Price Target to $70

Benzinga · 08/03 18:40
Citigroup analyst Geoff Meacham maintains Bristol-Myers Squibb (NYSE:BMY) with a Neutral and raises the price target from $66 to $70.